Endothelial Cell–Specific Inactivation of TSPAN12 (Tetraspanin 12) Reveals Pathological Consequences of Barrier Defects in an Otherwise Intact Vasculature

Chi Zhang,* Maria B. Lai,* Michelle G. Pedler, Verity Johnson, Ralf H. Adams, J. Mark Petrash, Zhe Chen, Harald J. Junge

Objective—Blood-CNS (central nervous system) barrier defects are implicated in retinopathies, neurodegenerative diseases, stroke, and epilepsy, yet, the pathological mechanisms downstream of barrier defects remain incompletely understood. Blood-retina barrier (BRB) formation and retinal angiogenesis require β-catenin signaling induced by the ligand norrin (NDP [Norrie disease protein]), the receptor FZD4 (frizzled 4), coreceptor LRP5 (low-density lipoprotein receptor-like protein 5), and the tetraspanin TSPAN12 (tetraspanin 12). Impaired NDP/FZD4 signaling causes familial exudative vitreoretinopathy, which may lead to blindness. This study sought to define cell type-specific functions of TSPAN12 in the retina.

Approach and Results—A loxP-flanked Tspan12 allele was generated and recombined in endothelial cells using a tamoxifen-inducible Cdh5-CreERT2 driver. Resulting phenotypes were documented using confocal microscopy. RNA-Seq, histopathologic analysis, and electroretinogram were performed on retinas of aged mice. We show that TSPAN12 functions in endothelial cells to promote vascular morphogenesis and BRB formation in developing mice and BRB maintenance in adult mice. Early loss of TSPAN12 in endothelial cells causes lack of intraretinal capillaries and increased VE-cadherin (CDH5 [cadherin5 aka VE-cadherin]) expression, consistent with premature vascular quiescence. Late loss of TSPAN12 strongly impairs BRB maintenance without affecting vascular morphogenesis, pericyte coverage, or perfusion. Long-term BRB defects are associated with immunoglobulin extravasation, complement deposition, cystoid edema, and impaired b-wave in electroretinograms. RNA-sequencing reveals transcriptional responses to the perturbation of the BRB, including genes involved in vascular basement membrane alterations in diabetic retinopathy.

Conclusions—This study establishes mice with late endothelial cell–specific loss of Tspan12 as a model to study pathological consequences of BRB impairment in an otherwise intact vasculature.

Visual Overview—An online visual overview is available for this article. (Arterioscler Thromb Vasc Biol. 2018;38:2691-2705. DOI: 10.1161/ATVBAHA.118.311689.)

Key Words: blood-brain barrier ■ diabetic retinopathy ■ edema ■ endothelial cells ■ inflammation

Blood-CNS (central nervous system) barrier defects are implicated in retinal and neurological disease. Retinal vascular diseases associated with dysregulated angiogenesis and impaired inner blood-retina barrier (BRB), for example, diabetic retinopathy (DR), are a leading cause of blindness, yet, the pathological consequences of barrier defects have been difficult to untangle from other vascular defects. Dysregulated angiogenesis and exudation are also encountered in familial exudative vitreoretinopathy and Norrie disease,8,9 which are caused by impaired NDP (Norrie disease protein)/FZD4 (frizzled 4) signaling. About 50% of familial exudative vitreoretinopathy cases are because of mutations in the genes encoding the ligand NDP, the receptor FZD4, LRP5 (low-density lipoprotein receptor-like protein 5, a coreceptor), or the coactivator TSPAN12 (tetraspanin 12). Tetraspanin membrane proteins function in diverse biological processes and are linked to human diseases, including cancer, retinal dystrophies, viral infections, and mental retardation. Tetraspanins engage in networks of direct and indirect protein-protein interactions, yet, the molecular basis for their biological activity is incompletely understood.
FZD4, LRP5, and TSPAN12 form a receptor complex for NDP, and each component of the complex is cointernalized during NDP-induced endocytosis of the receptor complex. We recently proposed that TSPAN12 is an NDP coreceptor that stabilizes the NDP/FZD4 interaction and enhances ligand selectivity of FZD4. A clear prediction of our model is that TSPAN12 functions in the same retinal cell type as FZD4 and LRP5, that is, in endothelial cells (ECs).

The role of canonical signaling in pathological vascular growth has been studied in models of retinopathies. In addition, NDP has also been studied in neuroprotection, regulation of tumor stroma, and regulation of neural progenitors. However, little is known about the role of NDP/FZD4 signaling in the mature vasculature.

Blood-CNS barrier formation in several developing CNS structures are induced by NDP, WNT7A, or WNT7B ligands, and β-catenin is a required mediator of signaling in ECs. Among the genes regulated by NDP/FZD4 signaling are regulators of vascular permeability and blood-CNS barrier function, for example, the fenestration component PLVAP (plasmalemma vesicle-associated protein, which is repressed by NDP/FZD4 signaling), the tight junction component Claudin-5, transporters that mediate selective transport into or out of the CNS, and transcription factors, including Sox (SRY-related HMG-box) F family members. However, whether BRB defects downstream of impaired NDP/FZD4 signaling cause retinal pathology, remains unknown.

**Nonstandard Abbreviations and Acronyms**

| Abbreviation | Definition |
|--------------|------------|
| BRB | blood-retina barrier |
| CDH5 | cadherin5 aka VE-cadherin |
| COL4 | collagen IV |
| DR | diabetic retinopathy |
| EC | endothelial cell |
| ECM | extracellular matrix |
| FITC | fluorescein isothiocyanate |
| FZD4 | frizzled 4 |
| LRP5 | low-density lipoprotein receptor-related protein 5 |
| MC | mural cell |
| MFAP | microfibrillar-associated protein |
| NDP | Norrie disease protein |
| PCR | polymerase chain reaction |
| PDGFβ | platelet-derived growth factor β |
| PECAM | platelet endothelial cell adhesion molecule |
| PKC | protein kinase C |
| PLVAP | plasmalemma vesicle-associated protein |
| S1P | sphingosine-1-phosphate |
| TGF | transforming growth factor |
| TSPAN12 | tetratspanin 12 |
| VE | vascular endothelial |
| VEGF | vascular endothelial growth factor |

how Wnt signaling mediates angiogenesis in the forebrain and ventral spinal cord is well understood.

Mouse models characterized by an impaired BRB have been developed for the purpose of studying DR. Models based on impaired PDGFβ signaling or hyperglycemia each exhibit compound pathologies that include loss of pericytes, perfusion defects, and hypoxia next to an impaired BRB. Thus, an animal model with normal vascular density, normal perfusion, normal pericyte coverage, yet strong BRB defects, is highly desirable to identify pathological consequences of BRB defects per se.

Here, we report that early EC-specific inactivation of the Tspan12 gene recapitulates phenotypes observed in Ndp, Fzd4, and Lrp5 mutant mice, consistent with a role of TSPAN12 in the NDP receptor complex. Induced recombination of Tspan12 bypasses vascular morphogenesis defects but reveals essential roles in BRB maintenance. Aged mice with long-term BRB defects display immunoglobulin accumulation in the retina, activation of antibody effector systems, cystoid edema, basement membrane alterations, and impaired electroretinogram. Thus, we reveal pathological mechanisms downstream of blood-CNS barrier defects in an otherwise intact vasculature.

**Materials and Methods**

**Data and Material Disclosure Statement**

The data and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure, pending material transfer agreement. RNA-Seq data have been deposited at NCBI GEO under accession GSE113878.

**Animals**

All animal work was done in accordance to the Association for Research in Vision and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research and with approval from the Institutional Animal Care and Use Committee at the University of Colorado. Animals of both genders were used for all studies. The following Cre-driver lines were used: Tg(Cdh5-cre/ERT2)1Rha, Pdgfrb(BAC)−CreERT2, and Rx-Cre, the latter kindly provided by Drs Eric Swindell and Milan Jamrich. miTmG reporter mice were obtained from Jackson Laboratories. Conditional knockout mice were generated by first breeding Tspan12 heterozygous mice with each Cre-driver line (heterozygous for the transgene), then breeding to generate knockout animals, and finally breeding to the right homology arms, each combined with a primer inside the right arm and left arms separately, using primers outside the left or outside the right arm, respectively.

**Gene Targeting**

The targeting construct for generating a Tspan12 floxed allele, pTspan12-LFNFL, contained the following sequence segments: exon3 (encoding the start codon and major portions of the first transmembrane segment) was flanked on the 3' end by a loxP site, and on the 5' end by an FRT-flanked PGK-neo-bGH cassette (for positive selection of ES cells) and the 5' loxP site. The 5' homologous arm (left arm) consisted of 2978 bp sequence containing exon1, exon2, and adjacent sequences. The 3' homologous arm (right arm) consisted of 2510 bp of intronic sequences downstream of exon3. The construct contained a thymidine kinase cassette outside the homology arms for negative selection of ES cells. The linearized construct was electroporated into EC7.1 ES cells and subjected to negative/positive selection with ganciclovir and G418, respectively. ES cell clones were screened using genomic polymerase chain reaction (PCRs) that amplified the right and left arms separately, using primers outside the left or outside the right homology arms, each combined with a primer inside the right arm.
targeting cassette. In addition, the entire targeted region was amplified using primers outside each homology arm. PCR products were further analyzed by restriction digestion. A karyotyped ES cell clone (D11) was injected into C57BL/6 blastocysts, and chimeras with germline transmission were identified by PCR. The FRT-flanked PGKneo cassette was removed by Flp recombination in the germ-line using FLp mice, and recombinant offspring was identified by PCR. A global knockout allele was generated by recombination of the loxP-flanked exon3 in the germline, using Ella-Cre. The knockout allele was genotyped using mTSPAN12_LA-fw oligo (5'-GTCTCAGGGCCATGACCAGT-3') and mTSPAN12_RA-rev oligo (5'-ACTACGGTGTCCCGAGTAGTCTGTG-3'), yielding a 256 bp ampiclon on the knockout allele and a 717 bp ampiclon on the wild-type allele. The floxed conditional allele was genotyped using mTSPAN12_LA-fw oligo (above) and TSP12ex3-rev oligo (5'-CCACATTTCTAGGTTCCAGGAGAG-3'), yielding a 403 bp ampiclon on the floxed allele and a 301 bp ampiclon on the wild-type allele. Mice were backcrossed on a C57BL/6J background.

Preparation and Administration of Tamoxifen
Tamoxifen (Sigma T5648) solutions were freshly prepared at 1 mg/mL in sterile corn oil (Sigma C8267) the day before each injection using a nutator to facilitate dissolution overnight at RT. Solutions were sterile filtered before injection. Fifty microliters of 1 mg/mL tamoxifen in corn oil was administrated in 4 IP injections spaced 2 days apart, starting at P28.

Immunofluorescent Staining
Retinas were processed and stained as described.31 The following primary antibodies and lectins were used for this study: GS Isolectin B4 Alexa-488 conjugate (Invitrogen, I21411), rat F4/80 1:200 (AbD Serotec, MCA497R), rabbit PKC 1:200 (Bethyl, A90-234A), goat IBA1 1:200 (Novus, NB100-2693), rabbit COL4 (collagen IV) 1:200 (Abcam, 6586), goat albumin (Cedarlane, CL7504AP), goat transferrin 1:200 (R&D, AF3987), Isolectin B4 Alexa-488 conjugate 1:100 (Invitrogen, I21411), rat IgG 1:200 (Jackson), rat F4/80 1:200 (AbD Serotec, MCA497R), rat PKC (protein kinase C) α 1:200 (Santa Cruz, C-20), and rabbit Sox9 1:200 (Millipore, AB5535). IgG1 was detected using Alexa555-coupled goat anti-mouse secondary antibody (Invitrogen). Other secondary antibodies were Alexa coupled (488, 555, and 647) and directed against rabbit, mouse, or rat (Invitrogen). Fluorescence was visualized using a Nikon A1 confocal laser scanning system or a Leica DM IL epifluorescent microscope.

 Branched DNA In Situ Hybridization
Twelve micrometer retinal sections at the level of the optic nerve head were collected. The assay was performed according to manufacturer instructions (QuantiGene ViewRNA ISH Tissue 1-Plex Assay Kit, Affymetrix). The branched DNA probe set was from Affymetrix (mTSPAN12: VB-16328) and was used at a 1:50 dilution. Immunostaining was performed subsequent to in situ hybridization.

Quantification of Pericyte Coverage
Confocal images were processed using the ImageJ colocalization plugin. Colocalization of desmin and PECAM was determined and normalized by the PECAM signal. Four images per retina and 3 to 4 retinas per genotype were analyzed.

Retinal Lysates
Two retinas from an P8-10 animal were dissected in cold PBS and homogenized in a 2 mL tube with 0.3 mL lysis buffer (150 mmol/L NaCl, 50 mmol/L Tris pH 8.0, 1 mmol/L CaCl2, 1% NP40, 0.1% N-dodecyl-β-D-maltoside, 3 mmol/L MgCl2, and DNAseI 80 units/mL (Roche), 1x complete ultra EDTA-free protease inhibitor cocktail (Roche)) using an electrical homogenizer (Omini). Proteins were extracted for 40 minutes on ice with gentle shaking. Cell debris and unsolubilized material were removed by 20,000g centrifugation at 4°C for 30 minutes. One hundred four micro liter supernatant, 40 µL 4x LDS (NuPAGE), and 16 µL 1 mol/L dithiothreitol were combined and incubated at 70°C for 10 minutes. Forty microliters of the sample were loaded per lane. VE-cadherin was detected using Millipore anti-VE-cadherin clone VI37 (MAB8786) at 1:1000. PECAM (cell signaling, 77699) and β-actin (Novus, NB600-501H) were probed as loading control.

Fluorescein Isothiocyanate-Dextran Perfusion
Mice were anesthetized with Ketamine/Xylazine 150/10 mg/kg. Unresponsive mice were perfused through the left ventricle with 2 mL of PBS containing 500 units of heparin (Millipore), followed by 10 mL PBS containing 1.5 mg/mL fluorescein isothiocyanate (FITC) conjugated Dextran (500 kDa, Sigma). Perfused retinas were then immediately immersion-fixed and stained as described.32

RNA-sequencing
Seven-month-old mice (tamoxifen at P28) were used to extract total RNA from 4 retinas per genotype (8 samples). DNA was digested (Turbo DNase free, Ambion), and RNA was ribodepleted (Ribozero RNA removal kit, Illumina). RNA integrity numbers were >8. Library preparation and sequencing were performed at the CU Anschutz Microarray and Genomics Core. Libraries were prepared using the Illumina TrueSeq Stranded Total RNA Library Prep Kit (RS-122–2202), and 300 bp fragments were isolated. High output 150 bp paired-end sequencing was performed on 1 lane of an Illumina HighSeq4000 instrument, resulting in 38 to 50 mio reads per sample. The following barcodes were used: 1L_WT1, ATATTCTG; 1R_WT2, TCCGGAGA; 5L_WT3, CGCTCATT; 5R_WT4, GAGATTCC; 10L_CKO1, ATTCAGAA; 10R_CKO2, GAATTCGT; 17L_CKO3, TCTAGAGCT; and 17R_CKO4, TAATGCGCC. The average reads/ bases quality was at least 93% ≥Q30. Reads were mapped against mouse genome GRCm38.p4 C57BL6J using the DSTAR (version 15) Seqman NGen RNA-Seq module. Among the most highly expressed genes were photoreceptor genes (eg, rhodopsin RPKM >8 per kilobase million 7034 in wild type). Genes expressed in ECs or microglia were expressed at lower levels (eg, IBA-1/ Aif1 RPKM 0.3). Differential gene expression analysis, filtering of genes of interest, and statistical tests were performed in the Arraystar module. Multiple testing correction within the set of 45802 coding and noncoding features was performed with Arraystar moderated t test with Benjamini-Hochberg false discovery rate determination. A list of protein-coding genes was created by filtering genes with RPKM ≥2- and ≥2.5-fold change or RPKM ≥2.0- and ≥2.0-fold change. These gene sets were combined and filtered for P≤0.05. Nonprotein coding genes were removed. The resulting gene list was subjected to gene ontology analyses in Arraystar (using MGI mouse GO terms) and in the DAVID resource. A list of selected genes of interest is shown in the Table. The processed data file showing the expression of all genes and the raw data files are available at NCBI GEO under accession GSE113878. Filenames ending on R1 indicate 3′ to 3′ reads, 3′ to 5′ reads were designated R2.

Electroretinogram
All animals were dark-adapted overnight. Electroretinograms were acquired under red light. Eyes were dilated with 0.5% tropicamide (Akron) and 2% phenylephrine (Paragon BioTech) and then anesthetized with 90 mg/kg ketamine and 10 mg/kg xylazine (both VetOne). Just before electroretinogram was performed a drop of 2.5 % hypromellose ophthalmic demulcent solution (Akron) was placed onto the cornea. Electroretinograms were performed on a Celeris instrument (Diagnosys). The electrodes were placed onto the cornea, and an impedance of <5 KΩ was ascertained before a combined dark and light protocol (Diagnosys Espion software) was
| Gene Symbol | Description                                      | ECKO RPKM | WT RPKM | Fold change | P Value  |
|-------------|-------------------------------------------------|-----------|---------|-------------|----------|
| C1qa        | Complement component 1, q subcomponent, α-polypeptide | 9.55      | 3.18    | 3.01        | 0.0000509|
| C1qb        | Complement component 1, q subcomponent, β-polypeptide | 10.56     | 3.16    | 3.34        | 0.000162 |
| C1qc        | Complement component 1, q subcomponent, C chain | 5.66      | 1.58    | 3.58        | 0.000454 |
| C3ar1       | Complement component 3a receptor 1, C3a anaphylatoxin chemotactic receptor | 0.41      | 0.04    | 10.97       | 0.00144  |
| C4b         | Complement component 4B (Chido blood group)     | 4.63      | 0.57    | 8.13        | 0.00121  |
| Fcgr2b      | Fc receptor, IgG, low-affinity IIb              | 1.16      | 0.15    | 7.99        | 0.000696 |
| Fcgr3       | Fc receptor, IgG, low-affinity III              | 3.01      | 0.75    | 4.02        | 0.000557 |
| Fcrl1g      | Fc receptor, IgE, high-affinity I, γ-polypeptide | 3.17      | 0.88    | 3.59        | 0.00329  |
| Serping1    | Serine (or cysteine) peptidase inhibitor, clade G, member 1; C1 inhibitor | 8.12      | 2.23    | 3.64        | 0.000298 |
| Antibody effector systems                      |                     |           |         |             |          |
| C1qa        | Complement component 1, q subcomponent, α-polypeptide | 9.55      | 3.18    | 3.01        | 0.0000509|
| C1qb        | Complement component 1, q subcomponent, β-polypeptide | 10.56     | 3.16    | 3.34        | 0.000162 |
| C1qc        | Complement component 1, q subcomponent, C chain | 5.66      | 1.58    | 3.58        | 0.000454 |
| C3ar1       | Complement component 3a receptor 1, C3a anaphylatoxin chemotactic receptor | 0.41      | 0.04    | 10.97       | 0.00144  |
| C4b         | Complement component 4B (Chido blood group)     | 4.63      | 0.57    | 8.13        | 0.00121  |
| Fcgr2b      | Fc receptor, IgG, low-affinity IIb              | 1.16      | 0.15    | 7.99        | 0.000696 |
| Fcgr3       | Fc receptor, IgG, low-affinity III              | 3.01      | 0.75    | 4.02        | 0.000557 |
| Fcrl1g      | Fc receptor, IgE, high-affinity I, γ-polypeptide | 3.17      | 0.88    | 3.59        | 0.00329  |
| Serping1    | Serine (or cysteine) peptidase inhibitor, clade G, member 1; C1 inhibitor | 8.12      | 2.23    | 3.64        | 0.000298 |
| Chemokines                          |                     |           |         |             |          |
| Ccl12       | Chemokine (C-C motif) ligand 12, C-C motif chemokine 12 | 1.41      | 0.01    | 127.35      | 0.0189   |
| Cxcl10      | Chemokine (C-X-C motif) ligand 10, C-X-C motif chemokine 10 | 0.75      | 0.11    | 6.69        | 0.00116  |
| Immune process, other                      |                     |           |         |             |          |
| Adgre1      | Adhesion G protein-coupled receptor E1 (F4/80)   | 0.42      | 0.09    | 4.87        | 0.00152  |
| Cd68        | CD68 antigen                                    | 7.97      | 2.51    | 3.18        | 0.00106  |
| Cd74        | Invariant polypeptide of major histocompatibility complex, class II antigen-associated | 1.34      | 0.18    | 7.64        | 0.00793  |
| Cst7        | Cystatin F (leukocystatin), Cystatin F          | 0.51      | 0       | 187.28      | 0.00684  |
| Endou       | Endonuclease, polyU-specific; Poly(U)-specific endoribonuclease | 1.23      | 0.46    | 2.66        | 0.0019   |
| Edn2        | Endothelin 2                                    | 1.41      | 0.12    | 12.26       | 0.000222 |
| Egr1        | Early growth response 1                         | 37.45     | 10.18   | 3.68        | 0.000254 |
| Fcrls       | Fc receptor-like S                              | 0.77      | 0.03    | 30.26       | 0.0332   |
| H2-Aa       | Histocompatibility 2, class II antigen-associated | 0.6       | 0.01    | 58.45       | 0.0367   |
| Lgals3      | Lectin, galactose binding, soluble 3            | 1.4       | 0.38    | 3.7         | 0.0103   |
| Lirb4a      | Leukocyte immunoglobulin-like receptor, subfamily B, member 4A | 0.31      | 0.02    | 14.32       | 0.0606   |
| Mrc1        | Mannose receptor, C type 1; Macrophage mannose receptor 1 | 0.35      | 0.01    | 56.97       | 0.0142   |
| Ms4a6d      | Membrane-spanning 4-domains, subfamily A, member 6D | 0.3       | 0       | 95.43       | 0.0173   |
| Osnr        | Oncostatin M receptor                            | 5.66      | 2.05    | 2.76        | 0.000408 |
| Psmb8       | Proteasome subunit β type-8                      | 1.52      | 0.55    | 2.78        | 0.0313   |
| Ppp1r14b    | Protein phosphatase 1 regulatory subunit 14B     | 1.11      | 0.44    | 2.53        | 0.0271   |
| Rgcc        | Regulator of cell cycle, Regulator of cell cycle RGCC | 1.36      | 0.47    | 2.92        | 0.0201   |
| 2610528A11Rik | RIKEN cDNA 2610528A11 gene                      | 15.24     | 4.98    | 3.06        | 0.00353  |
| Slfn8       | Schlafen 8, Protein Slfn8                       | 0.5       | 0.02    | 25.77       | 0.0274   |
| Tnfrsf1a    | Tumor necrosis factor receptor superfamily, member 1a | 2.68      | 0.97    | 2.77        | 0.00913  |
| Trem2       | Triggering receptor expressed on myeloid cells 2 | 2.03      | 0.5     | 4.08        | 0.0196   |
| Extracellular matrix organization and remodeling |                     |           |         |             |          |
| Dcn         | Decorin                                         | 1.43      | 0.36    | 3.98        | 0.0246   |
| Fbln1       | Fibulin 1                                        | 2.04      | 0.2     | 10.15       | 0.0408   |
| Fmod        | Fibromodulin                                    | 1.3       | 0.46    | 2.83        | 0.0279   |
| Lad1        | Ladinin                                         | 1.78      | 0.61    | 2.92        | 0.00734  |
| Lgals3      | Lectin, galactose binding, soluble 3             | 1.4       | 0.38    | 3.7         | 0.0103   |
| Mfap2       | Microfibrillar-associated protein 2              | 3.46      | 1.34    | 2.58        | 0.0148   |
| Mfap4       | Microfibrillar-associated protein 4              | 1.3       | 0.11    | 11.88       | 0.0134   |

(Continued)
run. A- and b-wave amplitudes were determined under scotopic conditions (1 cd s/m²). B-wave amplitudes were also determined under photopic conditions (10 cd s/m²).

Software
Nikon NIS-Elements, ImageJ, DNASTAR Lasergene Genomics Suite V15, GraphPad Prism, Microsoft Office 2016, and Adobe Photoshop/ Illustrator CS6 were used for data analysis and figure preparation.

Statistics
For comparison of 2 groups, a Shapiro-Wilk test for normality was performed to determine if a parametric or nonparametric test was appropriate. If data passed the normality test, an F test for equality of variances and a 2-tailed, unpaired heteroscedastic or homoscedastic Student t test was performed. Where normalized data are presented, individual values were divided by the average of the control group before statistical analysis. For one data set in the electroretinogram panel (indicated in the figure legends) a nonparametric Mann-Whitney U test was performed. RNA-Seq data were analyzed for significance of differential gene expression using Arraystar statistics tool, which performs an unpaired, 2-tailed, equal variance Student t test. For multiple group comparison, a parametric test was performed using GraphPad Prism by 1-way ANOVA with Tukey post hoc.

Results
**Tspan12 mRNA Is Detected in Capillaries and the Neural Retina**
To define which retinal cell types express TSPAN12, we localized Tspan12 mRNA using a branched DNA (bDNA) signal amplification in situ hybridization assay. Tspan12 message was detected in the retinal vasculature, as well as in the ganglion cell layer and inner nuclear layer, whereas control sections showed no signal after amplification (Figure 1A and 1B). Several other bDNA probe sets that were processed in parallel for a separate study showed distinct and specific staining patterns. BRB Defects in Tspan12−/− Mice
To determine the cell type(s) in which TSPAN12 functions and to examine the role of TSPAN12 in the mature retina, we generated a LoxP-flanked allele (MGI allele symbol Tspan12 tm1.1Hjug, in the following Tspan12 flox), in which the critical exon 3 (containing the start codon and major portions of the first transmembrane segment) can be removed by Cre-mediated recombination (Figure 1C through 1E). To confirm that recombination indeed results in Tspan12 gene inactivation, we used EIIα-Cre to induce recombination in the germline, which generated conventional homozygous Tspan12−/− mice (in the following Tspan12−/−). Confocal depth projections of IB4-stained P16 retinas showed glomeruloid vascular malformations and a lack of intraretinal capillaries (Figure 1F and 1G), as reported for a previously generated null mutant. These strong BRB defects were associated with upregulation of the EC fenestration component PLVAP (Figure 1H and 1I), especially in veins.

| Gene Symbol | Description | ECKO RPKM | WT RPKM | Fold change | P Value |
|-------------|-------------|-----------|----------|-------------|---------|
| Optc        | Opticin     | 4.42      | 0.68     | 6.49        | 0.00598 |
| Vcan        | Versican, Versican core protein | 1.98 | 0.68 | 2.94 | 0.0233 |

**Antioxidant activity**
- **Gpx3**: Glutathione peroxidase 3 (28.45, 5.23, 5.44, 0.00581)
- **Mgst1**: Microsomal glutathione S-transferase 1 (3.22, 1.12, 2.86, 0.000985)
- **Sod3**: Superoxide dismutase 3, extracellular; extracellular superoxide dismutase (1.87, 0.68, 2.74, 0.0423)

**Transport**
- **Slc13a4**: Solute carrier family 13 (sodium/sulfate symporters), member 4; protein Slc13a4 (2.04, 0.35, 5.77, 0.0139)
- **Trt**: Transthyretin (10.94, 3.55, 3.08, 0.0138)
- **Trf**: Transferrin (43.54, 14.71, 2.96, 0.000207)

**Other**
- **A2m**: α-2-macroglobulin (5.59, 1.17, 4.79, 0.000307)
- **Ankrd7**: Ankyrin repeat domain 7 (0.52, 1.45, 0.36, 0.000498)
- **Crybb1**: Crystallin, β B1 (0.58, 0, 190.01, 0.008)
- **Gfap**: Glial fibrillary acidic protein (16.83, 3.22, 5.23, 0.00033)
- **Rtkn2**: Rhotekin 2, Rhotekin-2 (0.42, 4.77, 0.09, 0.00000626)
- **Ptgds**: Prostaglandin D2 synthase (brain) (29.09, 11.35, 2.56, 0.001)

Selected genes are alphabetically ordered within each biological process heading. Multiple testing correction within the set of 45802 coding and noncoding features was performed with Arraystar moderated t test with Benjamini-Hochberg FDR determination, none of the listed genes reached q<0.05. FDR indicates false discovery rate; RPKM, reads per kilobase million; and WT, wild type.
Large Vessel Defects and Increased VE-Cadherin Expression in Tspan12−/− Mice

During this analysis, additional large vessel defects became apparent. The number of large vessels in P6-7 retinas was significantly increased in Tspan12−/− retinas (Figure IA and IB in the online-only Data Supplement), and aberrant arterial-venous crossings were observed (Figure IC and ID in the online-only Data Supplement). Both types of large vessel defects likely reflect impaired remodeling of the immature vascular plexus. Thus, consistent with previous reports on the role of NDP/FZD4 signaling in the retinal vasculature,15,26,55 we find that global Tspan12 inactivation results in BRB defects and abnormal arterial-venous crossings. The VEC-specific adhesion molecule CDH5 (cadherin5 [aka VE-cadherin]) is a coregulator of EC behavior, including vascular integrity and quiescence. We found that the adhesion molecule is upregulated in ECs of P6 Tspan12−/− retinas. Quantification of immunofluorescence staining intensity (Figure 2A through 2C) and immunoblot VE-cadherin band intensity from total retina lysates (Figure 2D and 2E) showed that VE-cadherin is about 2.5-fold more abundant in mutant retinas than in wild type. The upregulation of the mediator of vascular quiescence correlates with sluggish sprouting angiogenesis and large vessel defects in Tspan12 mutant mice. This finding provides novel insights into how impaired NDP/FZD4 signaling and defective angiogenesis are linked.

Tspan12 Functions in Retinal VECs

Next, we used Cdh5(PAC)-CreERT2,50 Pdgfrb(BAC)-CreERT2,51 and Rx-Cre52 to examine the role of TSPAN12 in ECs, mural cells (MCs), and cells derived from retinal precursors, respectively. Because Tspan12−/− heterozygotes show no substantial BRB or vascular morphogenesis defects (Figure 1F), we used Tspan12−/− mice positive for the respective Cre transgene, which facilitates removing TSPAN12 activity below the required levels. Tspan12−/−; Cdh5(PAC)-CreERT2 mice (ie, Tspan12 ECKO) displayed prominent BRB defects, lack of intraretinal capillaries, glomeruloid vascular malformations, and upregulated PLVAP expression (Figure 3A through 3E). In contrast, neither BRB defects nor vascular morphogenesis defects were detected in Tspan12−/−; Rx-Cre (Figure 3F and 3G) or Tspan12−/−; Pdgfrb(BAC)-CreERT2 mice (Figure 3H and 3I). Thus, TSPAN12 exerts angiogenic activity in ECs, the same cell type in which FZD4 and LR5 are required.15,16 This finding is consistent with a role of TSPAN12 as coreceptor in the NDP receptor complex.14

Reduced MC Coverage in Tspan12−/− Mice and Tspan12 ECKO Mice

Reduced MC coverage has been described as a consequence of impaired vascular β-catenin signaling15 and MCs are required for BRB formation.56 The intermediate filament desmin is a marker for pericytes and, to a lesser extent, other MC populations. Wild-type P7 mice showed a high coverage of small and larger blood vessels with desmin-positive cells; only few areas showed a lower degree of coverage (Figure IIA in the online-only Data Supplement). In contrast, P7 Tspan12−/− mice showed multiple areas with complete absence of desmin-positive cells (Figure IB in the online-only Data Supplement).

Quantification showed that MC coverage was reduced 31% (Figure IIC in the online-only Tspan12 Data Supplement). Analysis of P7 retinas after EC-specific Tspan12 inactivation (tamoxifen injection between P1 and P3) revealed non-cell autonomous MC coverage defects, which, however, were milder than in global Tspan12 knockout mice (Figure IID through IIF in the online-only Data Supplement). Examination of Tspan12−/− mice revealed no evidence for a cell-autonomous role of TSPAN12 in MCs (Figure IIG through III in the online-only Data Supplement). Experiments with mT/mG reporter mice showed that each Cre driver was efficient in inducing recombination (Figure III in the online-only Data Supplement).

TSPAN12 Is Required for BRB Maintenance but Is Dispensable for Vascular Maintenance or MC Coverage

We induced EC-specific inactivation of Tspan12 in ECs at P28 and analyzed the mice 1 and 6 months later. Massive IgG extravasation was detected at time points both 1 month and 6 months after recombination (Figure 4A through 4D). Confocal analysis of retinas at the 6-month post-recombination time point showed that all 3 retinal vascular layers were normally formed (Figure 4C and 4D). Coverage with desmin-positive cells was normal 6 months after EC-specific recombination in juvenile mice (Figure 4E through 4G), and retinas of either genotype were well-perfused with 500 kDa FITC-dextran via the transcardial route (Figure 4H and 4I). Therefore, late-induced recombination bypassed vascular morphogenesis and MC coverage defects, revealed a role for TSPAN12 in BRB maintenance, and provided a model to study pathological consequences of BRB defects in an otherwise intact vasculature.

RNA-Sequencing Reveals Activation of Antibody Effector Systems and Mediators of Matrix Organization and Remodeling

Sequencing of ribo-depleted retinal RNA revealed a significant transcriptional dysregulation 6 months after induction of BRB defects, with 6971 transcripts (coding and noncoding) showing 2-fold or higher differential expression. Differentially expressed genes were filtered according to differential expression, expression level, and significance criteria and subjected to gene ontology analysis (Table). Among the upregulated transcripts were multiple mediators of antibody effector systems, including components of the classical complement pathway (C1QA, C1QB, C1QC, and C4B). Complement 3A receptor 1 and the modulator of the complement pathway, SERPING1, were also upregulated. In addition, several transcripts encoding subunits of Fc receptors were increased. Other mediators of immune processes, many of which are known to be expressed in microglia, were overabundant, for example, ADGRE1 (aka F4/80). Markers of lymphoid cells were not expressed (ie, B-cell markers CD79A, CD79B; T-cells markers CD8B1, CD3D, CD3E, CD3G, and T-cell receptor constant or variable gene segments; NK cells markers KLRB1 [aka NK1.1], NCR1, CD27, and IL2RB). Myeloid differentiation marker GR1 (aka LY6G), which is expressed on granulocytes and peripheral neutrophils, and CCR2, a marker for...
blood monocytes, were also not expressed, indicating that leukocytes did not infiltrate the retina at the 6-month time point. However, chemokines, including CCL12 and CXCL10, were strongly upregulated, suggesting activation of microglia. Together, RNA-Seq data revealed involvement of the classical complement pathway as a major consequence of BRB defects.
Gene ontology analyses further revealed that transcripts encoding ECM (extracellular matrix) proteins, in particular proteins involved in ECM organization or remodeling of collagen and elastin fibers, were significantly elevated in mutant retinas. MFAPs (microfibrillar-associated proteins) 2 and 4, fibromodulin, fibulin 1, and decorin were in this group (Table). Several of these genes are implicated in vascular basement membrane alterations in DR or diabetic nephropathy (discussion).

**Impaired BRB Maintenance Is Associated With Complement Deposition, Cystoid Edema, and Basement Membrane Alterations**

Immunostaining of retinal sections from 1-year-old Tspan12 ECKO revealed that complement component C4, which is essential for the propagation of the classical complement pathway, was strongly increased in multiple foci in and around the inner nuclear layer of Tspan12 ECKO retinas, indicating localized complement deposition (Figure 5A). Foci of complement deposition were often associated with lesions in the inner nuclear layer and outer plexiform layer. H&E staining of a retinal section (displaying a relatively strongly affected area) showed that the appearance of the lesions is consistent with early stage cystoid edema (Figure 5B). Most cystoid lesions were heavily decorated with IgG and complement. Immunostaining further confirmed increased expression of F4/80 (ADGRE1 in the Table) in microglia, consistent with microglia activation (Figure 5C). Barrier defects resulted in increased extravasation of IgG, transferrin, and albumin (Figure 5D through 5F). Although IgG and albumin extravasation and increased C4 signal were already detectable 1 month after recombination, no lesions were present at early time points (Figure IV in the online-only Data Supplement).
Immunostaining also revealed a strongly increased signal for the basement membrane component COL4 surrounding intraretinal capillaries, whereas COL4 staining in the inner limiting membrane of Tspan12 ECKO retinas was unaltered, providing an internal reference (Figure 5G). In control retinas, vascular COL4 staining was substantially weaker. Genes encoding COL4 chains (COL4A1, COL4A2, COL4A3, COL4A4, COL4A5, and COL4A6) were not among the highly differentially expressed transcripts (0.9- to 1.4-fold change), suggesting that the increased abundance of COL4 in vascular basement membranes could be a consequence of altered matrix remodeling.

Costaining of C4 with IB4, rod-bipolar cell marker PKCα, nuclear Müller cell maker Sox9, microglia marker IBA-1, or with extravasated IgG, showed that C4 partially colocalized with mutant blood vessels, several cell populations of the inner nuclear layer, and microglia. Rod-bipolar cell and Müller glia cell populations appeared disorganized and displayed increased cell spacing (Figure 6). These observations suggest that the function of the inner retina may be impaired.

**Reduced b-Wave in Electroretinograms of Tspan12 ECKO Mice**

Electroretinograms were recorded to assess functional consequences of the pathology described in Tspan12 ECKO mice. Electroretinograms from 8 to 14-month-old, dark-adapted Tspan12 ECKO mice revealed a similar a-wave (predominantly...
caused by ion currents across photoreceptor membranes) compared with controls. In contrast, we detected a strong reduction of the b-wave (predominantly reflects ion currents across cell membranes in the inner retina) in both dark- and light-adapted Tspan12 ECKO mice (Figure 7A and 7B). Thus, the reduction of the b-wave and the location of retinal lesions in the inner nuclear layer and outer plexiform layer consistently indicate functional impairment of the inner retina. Together, our data link...
immunoglobulin extravasation, classical complement deposition, cystoid edema, and impaired neuronal function as consequences of an impaired BRB in an otherwise intact vasculature.

**Discussion**

We previously proposed that TSPAN12 functions as coreceptor in the norrin receptor complex. A prediction of this model is that TSPAN12 functions together with FZD4 and LRP5 in ECs, which is indeed the case.

CNS angiogenesis requires β-catenin-dependent signaling induced by WNT7A/B or NDP. How canonical signaling enables the vascularization of these CNS tissues is unclear. Interestingly, loss of canonical signaling is associated with a failure of tip cell formation in zebrafish CNS angiogenesis. We find that angiogenesis defects in the retina of Tspan12 mutant mice correlate with significantly increased VE-cadherin
expression in ECs. VE-cadherin is a key regulator of EC behavior. Importantly, VE-cadherin suppresses proangiogenic EC behavior—migration and proliferation—in mature blood vessels. Several factors that control EC behavior (e.g., VEGF [vascular endothelial growth factor] or S1P [sphingosine-1-phosphate]) impinge on VE-cadherin by altering its expression, controlling its internalization, or modifying its activity by phosphorylation. Conversely, VE-cadherin is physically associated with receptors, for example, VEGFR2 or TGFβ (transforming growth factor β) receptors, and modulates their activity. Our observation that VE-cadherin protein levels are roughly 2.5-fold increased in ECs of developing Tspan12 mutant mice suggests that canonical signaling suppresses VE-cadherin, perhaps transiently, to enable migration, proliferation, or tip cell formation. Indeed, EC-specific inactivation of Cdh5 (i.e., VE-cadherin), causes strong hypervascularization of the retina. Interestingly, intraretinal capillary formation is especially sensitive to loss of NDP/FZD4 signaling. A reduction of VE-cadherin may be required to reverse the quiescence of the superficial vascular plexus and enable vascularization of intraretinal layers.

**Figure 7.** Impaired b-wave in electoretinograms of aged Tspan12 ECKO mice. A, Example of electoretinograms recorded under dark-adapted and light-adapted conditions. B, B-wave amplitudes are significantly reduced in Tspan12 ECKO mice. N=12 (control) or n=6 (ECKO) retinas, average amplitude+SEM shown. Data for light-adapted b-waves were tested for significance using a nonparametric Mann-Whitney U test.

Among the long-term consequences of BRB defects are cystoid edema and impairment of retinal neural circuit function. These defects are accompanied by inflammation, vascular basement membrane alterations, and increased expression of oxidative stress defense genes (Table). Importantly, BRB impairment, cystoid edema, reduced b-wave and oscillatory potentials, inflammation, basement membrane thickening, and oxidative stress are also among the pathological changes observed in DR, implying that BRB defects in an otherwise intact vasculature are sufficient...
to recapitulate several key aspects of the DR pathology. Changes of microvascular BM composition and BM thickening are characteristic pathological features of DR and are associated with increased COL4 deposition.64 Interestingly, the increased COL4 deposition in Tspan12 ECKO mice is linked to increased expression of several genes involved in ECM organization and remodeling of collagen and elastic fibers. Several of the genes, including MAFAP4, fibulin 1, and small proteoglycans decorin and fibromodulin, are also overabundant in DR or diabetic nephropathy.55–64 Together, Tspan12 ECKO mice provide a model to untangle the specific pathological consequences of BRB disruption from compounding vascular pathologies observed in pericyte-deficient mice and hyalogenic animals. Surprisingly, BRB disruption per se is sufficient to recapitulate several characteristics of DR pathology. Furthermore, our findings show how BRB impairment contributes to vision impairment in familial exudative vitreoretinopathy. In a broader view, our findings provide insight into pathological mechanisms downstream of blood-CNS barrier impairment in neurologic disease.

Acknowledgments

We thank Dr James Orth in the MCDB light microscopy core facility for assistance in confocal imaging, Micah Stoltz in the animal facility for assistance, the Denver Gene-Targeted Vector Generation, Transgenic and Gene Targeting, and Microarray and Genomics core facilities at the Anschutz Medical Campus in Denver for support, Drs Eric Swindell and Milan Jamrich for providing Rx-Cre mice.

Sources of Funding

This work was supported in part by the Boettcher Foundation Webb-Waring Biomedical Research Award (to H.J. Junge), grants from the National Institutes of Health (EY024261 to H.J. Junge, and EY008586 and EY028147 to J.M. Petrash), and a challenge grant from Research to Prevent Blindness (to Department of Ophthalmology, University of Colorado).

Disclosures

C. Zhang, M.B. Lai, and H.J. Junge wrote the article. All authors edited the article.

References

1. Kempen JH, O’Colmain BJ, Leslie MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF. Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552–563. doi: 10.1001/archoph.122.4.552
2. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol. 2011;21(suppl 6):S3–S9. doi: 10.5301/ejio.2010.6049
3. Eshaghi RS, Aldalati AMZ, Alexander JS, Harris NR. Diabetic retinopathy: breaking the barrier. Pathophysiology. 2017;24:229–241. doi: 10.1016/j.pathophys.2017.07.001
4. Gilmour DF. Familial exudative vitreoretinopathy and related retinopathies. Eye (Lond). 2015;29:1–14. doi: 10.1038/eye.2014.70
5. Nikopoulos K, Venselaar H, Collin RW, et al. Overview of the mutation spectrum in familial exudative vitreoretinopathy and Norrie disease with identification of 21 novel variants in FZD4, LRPS5, and NDP. Hum Mutat. 2010;31:656–666. doi: 10.1002/humu.21250
6. Ye X, Wang Y, Nathans J. The norrin/frizzled4 signaling pathway in retinal vascular development and disease. Trends Mol Med. 2010;16:417–425. doi: 10.1016/j.molmed.2010.07.003
7. Nikopoulos K, Gilissen C, Hoischen A, et al. Next-generation sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy. Am J Hum Genet. 2010;86:240–247. doi: 10.1016/j.ajhg.2009.12.016
8. Poulter JA, Ali M, Gilmour DF, et al. Mutations in TSPAN12 cause autosomal-dominant familial exudative vitreoretinopathy. Am J Hum Genet. 2010;86:248–253. doi: 10.1016/j.ajhg.2010.01.012
9. Charrin S, Jouannot S, Bouchez C, Rubinstein E. Tetrapsamins at a glance. J Cell Sci. 2014;127(pt 17):3641–3648. doi: 10.1242/jcs.154906
10. van Deventer SJ, Dunlove VE, van Sprìel AB. Molecular interactions shaping the tetraspanin web. Biochem Soc Trans. 2017;45:741–750. doi: 10.1042/BST20160284
11. Zimmerman B, Kelly B, McMillan BJ, Seegar TC, Doro RO, Kruse AC, Blacklow SC. Crystal structure of a full-length human tetrapsarin reveals a cholesterol-binding pocket. Cell. 2016;167:1041.e1–1051.e11. doi: 10.1016/j.cell.2016.09.056
12. Junge HJ, Yang S, Burton JB, Pae K, Shu X, French DM, Costa M, Rice DS, Ye W. TSPAN12 regulates retinal vascular development by promoting norrin- but not Wnt-induced FZD4-beta-catenin signaling. Cell. 2009;139:299–311. doi: 10.1016/j.cell.2009.07.048
13. Zhang C, Lai MB, Khandan L, Lee LA, Chen Z, Junge HJ. Norrin-induced frizzled4 endocytosis and endo-lysosomal trafficking control retinal angiogenesis and barrier function. Nat Commun. 2017;8:16050. doi: 10.1038/ncomms16050
14. Lai MB, Zhang C, Shi J, Johnson V, Khandan L, McVey J, Klymkowski MW, Chen Z, Junge HJ. TSPAN12 is a norrin co-receptor that amplifies frizzled4 ligand selectivity and signaling. Cell Rep. 2017;19:2809–2822. doi: 10.1016/j.celrep.2017.06.004
15. Ye X, Wang Y, Cahill H, Yu M, Badea TC, Smallwood PM, Peachey NS, Nathans J. Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. Cell. 2009;139:285–298. doi: 10.1016/j.cell.2009.07.047
16. Huang W, Li Q, Amiri-Moghaddam M, Hokama M, Sardi SH, Nagao M, Warman ML, Osen BR. Critical endothelial regulation by LRPS during retinal vascular development. PLoS One. 2016;11:e0152833. doi: 10.1371/journal.pone.0152833
17. Chen J, Stahl A, Kraft NM, Meadow SR, Dennison JR, Sapieha P, Hua J, Hatton CJ, Juan AM, Aderman CM, Willet KL, Guerin KI, Mammoto A, Campbell M, Smith LE. Wnt signaling mediates pathological vascular growth in proliferative retinopathy. Circulation. 2011;124:1871–1881. doi: 10.1161/CIRCULATIONAHA.111.040337
18. Ohlmann A, Seitz R, Braunger B, Seitz D, Bisel MR, Tamm ER. Norrin promotes vascular regrowth after oxygen-induced retinal vessel loss and suppresses retinopathy in mice. J Neurosci. 2010;30:183–193. doi: 10.1523/JNEUROSCI.3210-09.2010
19. Chen Q, Ma JL. Canonical Wnt signaling in diabetic retinopathy. Vision Res. 2017;139:47–58. doi: 10.1016/j.visres.2017.02.022
20. Ohlmann A, Tamm ER. Norrin: molecular and functional properties of an angiogenic and neuroprotective growth factor. Prog Retin Eye Res. 2012;31:243–257. doi: 10.1016/j.preteyeres.2012.02.002
21. Bassett EA, Tokarew N, Allemano EA, et al. Norrin/frizzled4 signaling in the preneoplastic niche blocks medulloblastoma initiation. Elife. 2016;5:e16764. doi: 10.7554/eLife.16764
22. McNeill B, Mazerolle C, Bassett EA, Mears AJ, Ringuette R, Lagali P, Picketts DJ, Pae K, Rice D, Wallace VA. Hedgehog regulates Norrie disease protein to drive neural progenitor self-renewal. Hum Mol Genet. 2013;22:1005–1016. doi: 10.1093/hmg/ddt505
23. Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, Reis M, Felici A, Blacklow H, Fruttiger M, Takeo MM, von Melchner H, Plate KH, Gerhardt H, Dejana E, Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Bio. 2008;183:409–417. doi: 10.1083/jcb.200806024
24. Daneman R, Agullia D, Zhou L, Kuhnert F, Kuo CJ, Barres BA. Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc Natl Acad Sci USA. 2009;106:641–646. doi: 10.1073/pnas.0805165106
25. Stemman JM, Rajagopal J, Carroll TJ, Ishibashi M, McMahon JA, McMahon AP. Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science. 2008;322:1247–1250. doi: 10.1126/science.1164594
2704  Arterioscler Thromb Vasc Biol

27. Zhou Y, Wang Y, Tischfield M, Williams J, Smallwood PM, Rattner A, Nathans J. Vascular development in sprouting angiogenesis during development of the retinal vasculature. *Invest Ophthalmol Vis Sci*. 2008;50:906–916. doi: 10.1167/iovs.08-1731

28. Swindell EC, Bailey TJ, Venkatesan S, Fässler R, Fitch F, Liu C, Amaya-Manzanares F, Mahon KA, Wittbrodt J, Janoth M, Rs-Cre, a tool for inactivation of gene expression in the developing retina. *Genesis*. 2006;44:361–363. doi: 10.1002/dvg.20225

29. Jiang X, Yang L, Luo Y. Animal models of diabetic retinopathy. *Curr Eye Res*. 2015;40:761–771. doi: 10.3109/02713683.2014.964415

30. Park DY, Lee J, Kim J, Kim K, Hong S, Han S, Kubota Y, Augustin HG, Betsholtz C, Zlokovic BV. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. *Nature*. 2010;68:409–427. doi: 10.1038/neuro.2010.09.043

31. Chen Q, Zhang H, Liu Y, Adams S, Eiken H, Stehling M, Corada M, Dejana E, Zhou B, Adams R. Endothelial cells are progenitors of cardiac pericytes and vascular smooth muscle cells. *Nat Commun*. 2016;7:12422. doi: 10.1038/ncomms12422

32. Ulrich F, Carretero-Ortega J, Menéndez J, et al. Reck enables cerebrovascular development by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. *Neuron*. 2010;69:483–486. doi: 10.1016/j.neuron.2010.09.043

33. Chen J, Stahl A, Krah NM, Seaward MR, Joyal JS, Juan AM, Hatton C, Aderman CM, Dennison RJ, Willett KL, Sapieha P, Smith LE. Retinal expression of Wnt-pathway mediated genes in low-density lipoprotein receptor-related protein 5 (Lrp5) knockout mice. *PLoS One*. 2012;7:e30203. doi: 10.1371/journal.pone.0030203

34. Cullen M, Elzarrad MK, Seaman S, et al. GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier. *Proc Natl Acad Sci USA*. 2011;108:5759–5764. doi: 10.1073/pnas.1017192108

35. Zhou Y, Wang Y, Tischfield M, Williams J, Smallwood PM, Rattner A, Nathans J. Vascular development in sprouting angiogenesis during development of the retinal vasculature. *Invest Ophthalmol Vis Sci*. 2008;49:432–438. doi: 10.1167/iovs.07-1618

36. Schäfer NF, Luhmann UF, Feil S, Berger W. Differential gene expression in Ndpk-knockout mice in retinal development. *Invest Ophthalmol Vis Sci*. 2011;52:4260–4266. doi: 10.1167/iovs.11-7690

37. Schäfer NF, Luhmann UF, Feil S, Berger W. Differential gene expression in Ndpk-knockout mice in retinal development. *Invest Ophthalmol Vis Sci*. 2011;52:4260–4266. doi: 10.1167/iovs.11-7690

38. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Zhou Y, Wang Y, Tischfield M, Williams J, Smallwood PM, Rattner A, Nathans J. GPR124 controls CNS angiogenesis and blood-brain barrier regulation. *Cell* 2000;108:5759–5764. doi: 10.1073/pnas.1017192108

39. Zhou B, Adams R. Endothelial cells are progenitors of cardiac pericytes and vascular smooth muscle cells. *Nat Commun*. 2016;7:12422. doi: 10.1038/ncomms12422

40. Chi C, Smallwood PM, Nathans J. Reck and Gpr124 are essential receptor mediators of the retinal vascular condition FEVR. *Am J Hum Genet*. 2017;100:960–968. doi: 10.1016/j.ajhg.2017.05.001

41. Kuhnert F, Mancuso MR, Shamloo A, Wang HT, Choksi V, Florek pericytes and the retinal inner and inner ear: control by norrin and frizzled-4, a high-affinity lipoprotein receptor. *Dev Cell*. 2004;11:683–895

42. Panagiotou ES, Sanjurjo Soriano C, Poulter JA, et al. Defects in the retinal inner and inner ear: control by norrin and frizzled-4, a high-affinity lipoprotein receptor. *Dev Cell*. 2004;11:683–895

43. Xue Q, Yang Y, Daboub A, Smallwood PM, Williams J, Woods C, Kelley MW, Jiang L, Tasman W, Zhang K, Nathans J. Vascular development in the retina and inner ear: control by norrin and frizzled-4, a high-affinity lipoprotein receptor. *Cell*. 2004;116:36–48.

44. Choksi V, Florek pericytes and the retinal inner and inner ear: control by norrin and frizzled-4, a high-affinity lipoprotein receptor. *Dev Cell*. 2004;11:683–895

45. Schäfer NF, Luhmann UF, Feil S, Berger W. Differential gene expression in Ndpk-knockout mice in retinal development. *Invest Ophthalmol Vis Sci*. 2011;52:4260–4266. doi: 10.1167/iovs.11-7690

46. Enge M, Bjarnegård M, Gerhardt H, Gustafsson E, Kalén M, Asker N, Grauslund J. Association between microfibrillar-associated protein 1 (Mfap1) and micro- and macrovascular complications in type 2 diabetes mellitus. *PLoS One*. 2014;9:e90905. doi: 10.1371/journal.pone.0090002

47. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Zhou Y, Wang Y, Tischfield M, Williams J, Smallwood PM, Rattner A, Nathans J. GPR124 controls CNS angiogenesis and blood-brain barrier regulation. *Cell* 2000;108:5759–5764. doi: 10.1073/pnas.1017192108

48. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV. The sphingosine-1-phosphate receptor 5 (Lrp5) knockout mice. *J Cell Biol*. 2009;185:906–916. doi: 10.1016/j.jcb.2009.05.001

49. Gaengel K, Niaudet C, Hagikura K, et al. The sphingosine-1-phosphate receptor 5 (Lrp5) knockout mice. *J Cell Biol*. 2009;185:906–916. doi: 10.1016/j.jcb.2009.05.001

50. Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and dysfunction of the blood-brain barrier. *Cell*. 2015;163:1064–1078. doi: 10.1016/j.cell.2015.10.067

51. Giannotta M, Trani M, Dejana E. VE-cadherin and endothelial adherens junctions: active guardsians of vascular integrity. *Dev Cell*. 2013;26:441–454. doi: 10.1016/j.devcel.2013.08.020

52. Hammes HP, Shani M, Fässler R, Betsholtz C, Zhou B, Adams R. Norrin-induced angiogenesis and lymphangiogenesis. *Nature*. 2010;465:483–486. doi: 10.1038/nature09002

53. Choksi V, Florek pericytes and the retinal inner and inner ear: control by norrin and frizzled-4, a high-affinity lipoprotein receptor. *Dev Cell*. 2004;11:683–895

54. Yamamoto H, Ehling M, Kato K, Kanai K, van Lessen M, Frye M, Zha Z, Zhang H, Friedlander M, Yea K. Antibody-mediated inhibition of Tspan12 ameliorates vasoproliferative retinopathy through suppression of β-catenin signaling. *Circulation*. 2010;122:1850–1855. doi: 10.1161/CIRCULATIONAHA.110.196681

55. Park DY, Lee J, Kim J, Kim K, Hong S, Han S, Kubota Y, Augustin HG, Ding L, Kim JW, Kim H, He Y, Adams RH, Koh YG. Plastic roles of pericytes in the blood-retinal barrier. *Nat Commun*. 2017;8:15296. doi: 10.1038/ncomms15296
long-term type 1 diabetes mellitus. *Acta Diabetol*. 2017;54:367–372. doi: 10.1007/s00592-016-0953-y

66. Schaefer L, Raslik I, Grone HJ, Schonherr E, Macakova K, Ugorcakova J, Budny S, Schaefer RM, Kresse H. Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. *FASEB J*. 2001;15:559–561. doi: 10.1096/fj.00-0493fje

67. Cangemi C, Skov V, Poulsen MK, et al. Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. *Clin Chem*. 2011;57:1556–1565. doi: 10.1373/clinchem.2011.162966

68. Freeman WM, Bixler GV, Brucklacher RM, Walsh E, Kimball SR, Jefferson LS, Bronson SK. Transcriptomic comparison of the retina in two mouse models of diabetes. *J Ocul Biol Dis Infor*. 2009;2:202–213. doi: 10.1007/s12177-009-9045-3

**Highlights**

- Conditional genetics reveal endothelial cell–specific functions of TSPAN12 (tetraspanin 12) in retinal angiogenesis and barriergenesis during development.
- TSPAN12 is required for blood-retina barrier maintenance but is dispensable for vascular maintenance, mural cell coverage, or perfusion in mature mice.
- Late-induced TSPAN12 ECKO mice provide a model to study barrier defects in an otherwise intact vasculature.
- Barrier defects are associated with IgG extravasation, complement deposition, cystoid edema, and reduced electroretinogram b-wave.
- RNA-Seq reveals dysregulation of ECM (extracellular matrix), akin to diabetic retinopathy.